Login to Your Account

VIA Pops on Subset Analysis from Phase II ACS Trial with VIA-2291

By Trista Morrison

Monday, May 4, 2009
Shares of VIA Pharmaceuticals Inc. jumped 45 percent Friday after the company presented a Phase II subset analysis showing that VIA-2291 reduced unstable coronary plaques in patients with acute coronary syndrome. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription